Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting human melanoma neoantigens by T cell receptor gene therapy.
Leisegang M, Kammertoens T, Uckert W, Blankenstein T. Leisegang M, et al. Among authors: kammertoens t. J Clin Invest. 2016 Mar 1;126(3):854-8. doi: 10.1172/JCI83465. Epub 2016 Jan 25. J Clin Invest. 2016. PMID: 26808500 Free PMC article.
Making and circumventing tolerance to cancer.
Kammertoens T, Blankenstein T. Kammertoens T, et al. Eur J Immunol. 2009 Sep;39(9):2345-53. doi: 10.1002/eji.200939612. Eur J Immunol. 2009. PMID: 19634191
Even though the mutations that cause cancer can create new antigens that are potentially "visible" to T cells, in most experimental model systems the growth of tumors is accompanied by induction of T-cell tolerance towards the tumor. ...Effective adoptive T-c …
Even though the mutations that cause cancer can create new antigens that are potentially "visible" to T cells, in most experimental m …
High Salt Inhibits Tumor Growth by Enhancing Anti-tumor Immunity.
Willebrand R, Hamad I, Van Zeebroeck L, Kiss M, Bruderek K, Geuzens A, Swinnen D, Côrte-Real BF, Markó L, Lebegge E, Laoui D, Kemna J, Kammertoens T, Brandau S, Van Ginderachter JA, Kleinewietfeld M. Willebrand R, et al. Among authors: kammertoens t. Front Immunol. 2019 Jun 4;10:1141. doi: 10.3389/fimmu.2019.01141. eCollection 2019. Front Immunol. 2019. PMID: 31214164 Free PMC article.
Interferon-γ Receptor Signaling in Dendritic Cells Restrains Spontaneous Proliferation of CD4+ T Cells in Chronic Lymphopenic Mice.
Knop L, Frommer C, Stoycheva D, Deiser K, Kalinke U, Blankenstein T, Kammertoens T, Dunay IR, Schüler T. Knop L, et al. Among authors: kammertoens t. Front Immunol. 2019 Feb 7;10:140. doi: 10.3389/fimmu.2019.00140. eCollection 2019. Front Immunol. 2019. PMID: 30792713 Free PMC article.
Fas expression by tumor stroma is required for cancer eradication.
Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C, Blankenstein T. Listopad JJ, et al. Among authors: kammertoens t. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2276-81. doi: 10.1073/pnas.1218295110. Epub 2013 Jan 22. Proc Natl Acad Sci U S A. 2013. PMID: 23341634 Free PMC article.
The contribution of molecules such as perforin, IFN-γ (IFNγ), and particularly Fas ligand (FasL) by transferred CD8(+) effector T (T(E)) cells to rejection of large, established tumors is incompletely understood. ...Here, initial regression of large, established tum …
The contribution of molecules such as perforin, IFN-γ (IFNγ), and particularly Fas ligand (FasL) by transferred CD8(+) effector T ( …
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, Sommermeyer D, Engels B, Leisegang M, Textor A, Fehling HJ, Fruttiger M, Lohoff M, Herrmann A, Yu H, Weichselbaum R, Uckert W, Hübner N, Gerhardt H, Beule D, Schreiber H, Blankenstein T. Kammertoens T, et al. Nature. 2017 May 4;545(7652):98-102. doi: 10.1038/nature22311. Epub 2017 Apr 26. Nature. 2017. PMID: 28445461 Free PMC article.
Targeting c-MYC with T-cells.
Helm F, Kammertoens T, Lehmann FM, Wilke A, Bruns H, Mautner J, Bornkamm GW, Gerbitz A. Helm F, et al. Among authors: kammertoens t. PLoS One. 2013 Oct 10;8(10):e77375. doi: 10.1371/journal.pone.0077375. eCollection 2013. PLoS One. 2013. PMID: 24130880 Free PMC article.
Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J. Stelljes M, et al. Among authors: kammertoens t. Blood. 2004 Aug 15;104(4):1210-6. doi: 10.1182/blood-2003-10-3387. Epub 2004 Apr 15. Blood. 2004. PMID: 15090450
Adoptive transfer of the effector cells into secondary tumor-bearing recipients confirmed sustained antitumor activity and specificity of the T-cell response. The results provide experimental proof of a donor CD8+ T cell-mediated TAA-specific antitumor response in v …
Adoptive transfer of the effector cells into secondary tumor-bearing recipients confirmed sustained antitumor activity and specificity of th …
Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.
Briesemeister D, Sommermeyer D, Loddenkemper C, Loew R, Uckert W, Blankenstein T, Kammertoens T. Briesemeister D, et al. Among authors: kammertoens t. Int J Cancer. 2011 Jan 15;128(2):371-8. doi: 10.1002/ijc.25350. Epub 2010 Mar 23. Int J Cancer. 2011. PMID: 20333679
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. Qin Z, et al. Among authors: kammertoens t. Cancer Res. 2003 Jul 15;63(14):4095-100. Cancer Res. 2003. PMID: 12874012
It is thought that tumor rejection by CD8(+) T-cell effectors is primarily mediated by direct killing. We show that rejection of different tumors (fibrosarcoma, ras-transformed fibroblasts, colon carcinoma, and plasmacytoma) by CD8(+) T cells is always preceded by i …
It is thought that tumor rejection by CD8(+) T-cell effectors is primarily mediated by direct killing. We show that rejection of diff …
38 results
Jump to page
Feedback